The Analyst Verdict: Alignment Healthcare In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings over the past three months, with 2 bullish and 3 indifferent ratings. The average 12-month price target is $9.45, up 11.18% from the previous $8.50. Analysts from Raymond James, UBS, B of A Securities, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown a revenue growth of 26.74% as of September 30, 2023, but struggles with profitability and debt management, having a net margin of -7.67% and a debt-to-equity ratio of 0.91.
January 09, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed opinions on ALHC, with recent upgrades in price targets suggesting a positive outlook. However, concerns about profitability and debt management persist.
The increase in the average price target to $9.45 indicates a positive sentiment among analysts, which could lead to short-term bullishness in the stock price. However, the concerns about profitability and debt management could temper the optimism, suggesting a cautious approach to the stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100